Why a kidney disease drug approval in China is just the start for this S.F. company
To win its first-ever drug approval, FibroGen Inc. turned to China, but it's not going to be the San Francisco company's last stop.
China's drug regulatory agency Monday approved roxadustat, the first drug of its kind for dialysis patients with anemia caused by chronic kidney disease. San Francisco-based FibroGen's (NASDAQ: FGEN) China subsidiary will manufacture the tablet and partner AstraZeneca plc (NYSE: AZN) will sell the drug starting in the second-half of 2019.
But roxadustat's win in China…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Ron Leuty Source Type: news
More News: American Health | Anemia | AstraZeneca | China Health | Chronic Kidney Disease | Dialysis | Health Management | Urology & Nephrology